drugset / Trial / NCT00068471

Anidulafungin in Treating Immunocompromised Children With Neutropenia

NCT00068471 ↗

Phase 1/2 Completed National Cancer Institute (NCI)
Open-labelSupportive care

Summary

RATIONALE: Anidulafungin may be effective in preventing fungal infections in immunocompromised children who have neutropenia. PURPOSE: This phase I/II trial is studying the side effects of anidulafungin and to see how well it works in preventing fungal infections in immunocompromised children with neutropenia caused by chemotherapy or aplastic anemia.

Timeline

Start
2003-07
Primary completion
—
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Anidulafungin Other / unclassified — Intravenous